FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.
The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...
today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a ...
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
A new drug application is anticipated for 2029. The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...